Intec Pharma Stock Price, News & Analysis (NASDAQ:NTEC)

$5.63 -0.07 (-1.23 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$5.63
Today's Range$5.50 - $5.80
52-Week Range$4.20 - $9.80
Volume50,126 shs
Average Volume85,954 shs
Market Capitalization$148.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Intec Pharma (NASDAQ:NTEC)

Intec Pharma logoIntec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

Receive NTEC News and Ratings via Email

Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:NTEC
CUSIPN/A
Phone+972-2-5864657

Debt

Debt-to-Equity RatioN/A
Current Ratio19.92%
Quick Ratio19.92%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.98 per share
Price / Book2.84

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees56
Outstanding Shares26,080,000

Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) issued its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.09. View Intec Pharma's Earnings History.

When will Intec Pharma make its next earnings announcement?

Intec Pharma is scheduled to release their next quarterly earnings announcement on Friday, April, 6th 2018. View Earnings Estimates for Intec Pharma.

Where is Intec Pharma's stock going? Where will Intec Pharma's stock price be in 2018?

4 Wall Street analysts have issued 12-month target prices for Intec Pharma's shares. Their predictions range from $8.00 to $15.00. On average, they expect Intec Pharma's share price to reach $12.00 in the next twelve months. View Analyst Ratings for Intec Pharma.

What are Wall Street analysts saying about Intec Pharma stock?

Here are some recent quotes from research analysts about Intec Pharma stock:

  • 1. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (1/16/2018)
  • 2. Maxim Group analysts commented, "Intec reported 3Q17 with a net loss of $7.7M and ended the period with $63.0M in cash, including proceeds from a $57.5M equity financing. At the current burn rate, we estimate the company has runway into late 2019." (11/17/2017)

Who are some of Intec Pharma's key competitors?

Who are Intec Pharma's key executives?

Intec Pharma's management team includes the folowing people:

  • John W. Kozarich, Chairman of the Board (Age 67)
  • Jeffrey A. Meckler, Chief Executive Officer, Vice Chairman of the Board (Age 50)
  • Nir Sassi, Chief Financial Officer (Age 41)
  • Nadav Navon, Chief Operating Officer (Age 48)
  • Walt Addison Linscott, Chief Administrative Officer (Age 57)
  • Liat Flaishon, Vice President-Clinical and Business Development (Age 48)
  • R. Michael Gendreau, Chief Medical Officer (Age 62)

When did Intec Pharma IPO?

(NTEC) raised $30 million in an initial public offering on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.

Who owns Intec Pharma stock?

Intec Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Meitav Dash Investments Ltd. (6.41%), Millennium Management LLC (1.04%), Renaissance Technologies LLC (0.51%) and Deutsche Bank AG (0.44%). View Institutional Ownership Trends for Intec Pharma.

Who bought Intec Pharma stock? Who is buying Intec Pharma stock?

Intec Pharma's stock was bought by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., Millennium Management LLC, Renaissance Technologies LLC and Deutsche Bank AG. View Insider Buying and Selling for Intec Pharma.

How do I buy Intec Pharma stock?

Shares of Intec Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intec Pharma's stock price today?

One share of Intec Pharma stock can currently be purchased for approximately $5.63.

How big of a company is Intec Pharma?

Intec Pharma has a market capitalization of $148.60 million. Intec Pharma employs 56 workers across the globe.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 Hartom st. (RMPE building) Har Hotzvim P.O.Box 45219, JERUSALEM, 91450, Israel. The biotechnology company can be reached via phone at +972-2-5864657 or via email at [email protected]


MarketBeat Community Rating for Intec Pharma (NTEC)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  200
MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intec Pharma (NASDAQ:NTEC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.00$12.00$12.00$9.50
Price Target Upside: 142.42% upside142.42% upside112.39% upside79.25% upside

Intec Pharma (NASDAQ:NTEC) Consensus Price Target History

Price Target History for Intec Pharma (NASDAQ:NTEC)

Intec Pharma (NASDAQ:NTEC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/18/2017OppenheimerSet Price TargetBuy$15.00LowView Rating Details
11/17/2017Maxim GroupSet Price TargetBuy$9.00 -> $8.00N/AView Rating Details
9/21/2017CIBCReiterated RatingOutperform -> Outperform$10.00 -> $15.00MediumView Rating Details
8/10/2017Roth CapitalSet Price TargetBuy$10.00HighView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Intec Pharma (NASDAQ:NTEC) Earnings History and Estimates Chart

Earnings by Quarter for Intec Pharma (NASDAQ:NTEC)

Intec Pharma (NASDAQ NTEC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/6/2018        
11/15/2017Q3 2017($0.34)($0.40)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.47)ViewN/AView Earnings Details
4/7/2017Q4 2016($0.32)ViewN/AView Earnings Details
9/1/2016Q2 2016($0.37)($0.18)ViewN/AView Earnings Details
3/14/2016Q4 2015($0.10)($0.29)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.07)($0.16)ViewN/AView Earnings Details
8/31/2015Q2 2015($0.16)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Intec Pharma (NASDAQ:NTEC) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.35 EPS
Next Year EPS Consensus Estimate: $-0.89 EPS

Dividends

Dividend History for Intec Pharma (NASDAQ:NTEC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Intec Pharma (NASDAQ NTEC)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Intec Pharma (NASDAQ NTEC) News Headlines

Source:
DateHeadline
Intec Pharma Ltd (NTEC) Given Consensus Recommendation of "Buy" by AnalystsIntec Pharma Ltd (NTEC) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 18 at 1:30 AM
 Brokerages Expect Intec Pharma Ltd (NTEC) Will Post Earnings of -$0.19 Per Share Brokerages Expect Intec Pharma Ltd (NTEC) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - February 13 at 3:14 AM
Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical OfficerIntec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer
finance.yahoo.com - January 31 at 9:10 AM
Zacks: Analysts Anticipate Intec Pharma Ltd (NTEC) Will Announce Earnings of -$0.19 Per ShareZacks: Analysts Anticipate Intec Pharma Ltd (NTEC) Will Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - January 27 at 5:18 AM
Intec Pharma Ltd (NTEC) Receives Average Rating of "Buy" from AnalystsIntec Pharma Ltd (NTEC) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 24 at 1:44 AM
Critical Review: Proteostasis Therapeutics (PTI) & Intec Pharma (NTEC)Critical Review: Proteostasis Therapeutics (PTI) & Intec Pharma (NTEC)
www.americanbankingnews.com - January 22 at 3:14 PM
Zacks Investment Research Downgrades Intec Pharma (NTEC) to HoldZacks Investment Research Downgrades Intec Pharma (NTEC) to Hold
www.americanbankingnews.com - January 16 at 10:34 AM
Intec Pharma (NTEC) Raised to "Buy" at Zacks Investment ResearchIntec Pharma (NTEC) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 13 at 9:26 AM
Zacks: Analysts Anticipate Intec Pharma Ltd (NTEC) to Announce -$0.19 Earnings Per ShareZacks: Analysts Anticipate Intec Pharma Ltd (NTEC) to Announce -$0.19 Earnings Per Share
www.americanbankingnews.com - January 10 at 4:04 AM
Intec Pharma (NTEC) Reports Development Collaboration With Global Pharmaceutical CompanyIntec Pharma (NTEC) Reports Development Collaboration With Global Pharmaceutical Company
www.streetinsider.com - January 8 at 5:07 PM
BRIEF-Meitav Dash Investments Ltd Group Reports 7.18 Pct Passive Stake In Intec PharmaBRIEF-Meitav Dash Investments Ltd Group Reports 7.18 Pct Passive Stake In Intec Pharma
www.reuters.com - January 8 at 10:07 AM
Intec Pharma Announces Development Collaboration With Global Pharmaceutical CompanyIntec Pharma Announces Development Collaboration With Global Pharmaceutical Company
finance.yahoo.com - January 8 at 10:07 AM
Intec Pharma (NTEC) Rating Increased to Buy at Zacks Investment ResearchIntec Pharma (NTEC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 6 at 9:56 AM
Intec Pharma (NTEC) Lowered to Hold at Zacks Investment ResearchIntec Pharma (NTEC) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 3 at 3:30 PM
Intec Pharma Granted Patent in Canada for Accordion Pill™ Carbidopa / LevodopaIntec Pharma Granted Patent in Canada for Accordion Pill™ Carbidopa / Levodopa
finance.yahoo.com - January 3 at 9:10 AM
Intec Pharma Ltd (NTEC) Given Average Rating of "Buy" by BrokeragesIntec Pharma Ltd (NTEC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 30 at 1:50 AM
Intec Pharma (NTEC) versus Its Competitors Head-To-Head ReviewIntec Pharma (NTEC) versus Its Competitors Head-To-Head Review
www.americanbankingnews.com - December 25 at 3:26 PM
Intec Pharma (NTEC) Downgraded by Zacks Investment ResearchIntec Pharma (NTEC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - December 24 at 1:52 PM
Zacks Investment Research Upgrades Intec Pharma (NTEC) to "Buy"Zacks Investment Research Upgrades Intec Pharma (NTEC) to "Buy"
www.americanbankingnews.com - December 23 at 10:00 PM
Intec Pharma (NTEC) Given a $15.00 Price Target at OppenheimerIntec Pharma (NTEC) Given a $15.00 Price Target at Oppenheimer
www.americanbankingnews.com - December 18 at 11:46 AM
Head-To-Head Review: Intec Pharma (NTEC) and Its RivalsHead-To-Head Review: Intec Pharma (NTEC) and Its Rivals
www.americanbankingnews.com - December 16 at 11:08 PM
Intec Pharma Ltd. (NTEC) Receives Average Recommendation of "Buy" from BrokeragesIntec Pharma Ltd. (NTEC) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 5 at 1:38 AM
Zacks Investment Research Upgrades Intec Pharma Ltd. (NTEC) to "Buy"Zacks Investment Research Upgrades Intec Pharma Ltd. (NTEC) to "Buy"
www.americanbankingnews.com - November 23 at 9:16 PM
FY2017 Earnings Forecast for Intec Pharma Ltd. (NTEC) Issued By Oppenheimer HoldingsFY2017 Earnings Forecast for Intec Pharma Ltd. (NTEC) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 20 at 3:15 AM
-$0.19 EPS Expected for Intec Pharma Ltd. (NTEC) This Quarter-$0.19 EPS Expected for Intec Pharma Ltd. (NTEC) This Quarter
www.americanbankingnews.com - November 19 at 3:22 AM
Intec Pharma Ltd. (NTEC) PT Set at $15.00 by Oppenheimer Holdings, Inc.Intec Pharma Ltd. (NTEC) PT Set at $15.00 by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 18 at 7:34 PM
Intec Pharma Reports Third Quarter 2017 Operating and Financial ResultsIntec Pharma Reports Third Quarter 2017 Operating and Financial Results
finance.yahoo.com - November 18 at 9:04 AM
Maxim Group Analysts Give Intec Pharma Ltd. (NTEC) a $8.00 Price TargetMaxim Group Analysts Give Intec Pharma Ltd. (NTEC) a $8.00 Price Target
www.americanbankingnews.com - November 17 at 3:20 PM
Intec Pharma Ltd. (NTEC) Downgraded by ValuEngine to "Sell"Intec Pharma Ltd. (NTEC) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - November 16 at 11:34 PM
Intec Pharma Ltd. (NTEC) Receives Average Recommendation of "Buy" from AnalystsIntec Pharma Ltd. (NTEC) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 10 at 1:38 AM
Intec Pharma, Ltd. to Present at the Jefferies 2017 London Healthcare ConferenceIntec Pharma, Ltd. to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 9 at 9:39 AM
Intec Pharma Ltd. Announces Changes To Its Board Of DirectorsIntec Pharma Ltd. Announces Changes To Its Board Of Directors
www.thestreet.com - November 2 at 7:03 AM
Intec Pharma, Ltd. Announces Changes to its Board of DirectorsIntec Pharma, Ltd. Announces Changes to its Board of Directors
finance.yahoo.com - November 2 at 7:03 AM
Intec Pharma Names Walt Linscott as Chief Administrative OfficerIntec Pharma Names Walt Linscott as Chief Administrative Officer
finance.yahoo.com - October 27 at 8:42 AM
Intec Pharma Ltd. (NTEC) Given Average Recommendation of "Buy" by BrokeragesIntec Pharma Ltd. (NTEC) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 16 at 2:10 AM
Intec Pharma Ltd. (NTEC) Upgraded to "Hold" by Zacks Investment ResearchIntec Pharma Ltd. (NTEC) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - October 16 at 12:14 AM
Intec Pharma: Buy The DipIntec Pharma: Buy The Dip
seekingalpha.com - October 15 at 8:13 PM
Intec Pharma Ltd. (NTEC) Given a $15.00 Price Target by Oppenheimer Holdings, Inc. AnalystsIntec Pharma Ltd. (NTEC) Given a $15.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - October 14 at 12:12 PM
Intec Pharma to Participate in the Oppenheimer Specialty Pharma SummitIntec Pharma to Participate in the Oppenheimer Specialty Pharma Summit
finance.yahoo.com - October 6 at 9:59 AM
Pot Stock Winners of the WeekPot Stock Winners of the Week
finance.yahoo.com - October 5 at 12:32 PM
Intec Pharma Ltd. (NTEC) Forecasted to Post Q3 2017 Earnings of ($0.34) Per ShareIntec Pharma Ltd. (NTEC) Forecasted to Post Q3 2017 Earnings of ($0.34) Per Share
www.americanbankingnews.com - September 25 at 1:34 AM
Intec Pharma to Participate in the Ladenburg Thalmann 2017 Healthcare ConferenceIntec Pharma to Participate in the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 22 at 11:40 AM
Intec Pharma Ltd. (NTEC) Receives Consensus Recommendation of "Hold" from AnalystsIntec Pharma Ltd. (NTEC) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 21 at 10:40 AM
Intec Pharma Ltd. (NTEC) Receives "Outperform" Rating from CIBCIntec Pharma Ltd. (NTEC) Receives "Outperform" Rating from CIBC
www.americanbankingnews.com - September 21 at 10:22 AM
Intec Pharma Ltd. (NTEC) Price Target Raised to $15.00 at Oppenheimer Holdings, Inc.Intec Pharma Ltd. (NTEC) Price Target Raised to $15.00 at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 21 at 10:02 AM
Therapix Biosciences: Another Favorite Marijuana PlayTherapix Biosciences: Another Favorite Marijuana Play
seekingalpha.com - September 17 at 6:01 AM
BRIEF-Acuta Capital Partners reports 10.5 pct passive stake in Intec PharmaBRIEF-Acuta Capital Partners reports 10.5 pct passive stake in Intec Pharma
www.reuters.com - September 10 at 4:07 AM
Intec Pharma to Participate in the 19th Annual Rodman & Renshaw Global Investment ConferenceIntec Pharma to Participate in the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 9 at 6:47 AM
Intec Pharma to Participate in BioCenturys 24th Annual NewsMakers in the Biotech Industry ConferenceIntec Pharma to Participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference
finance.yahoo.com - September 2 at 6:56 AM
Intec Pharma (NTEC) Catches Eye: Stock Adds 9.8% in SessionIntec Pharma (NTEC) Catches Eye: Stock Adds 9.8% in Session
finance.yahoo.com - August 23 at 9:19 AM

SEC Filings

Intec Pharma (NASDAQ:NTEC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intec Pharma (NASDAQ:NTEC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intec Pharma (NASDAQ NTEC) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.